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Abstract
Interferon (IFN) regulatory factor 7 (IRF7) plays a key role in the production of IFNα in response 
to viral infection, and phosphorylation at IRF7 C-terminal serine sites is prelude to its function. 
However, no phosphatases which that may be involved in negatively regulate IRF7 
phosphorylation and activity has have not been reported. In this study, we have identified a 
conserved protein phosphatase 1 (PP1)-binding motif in human and mouse IRF7 proteins, and 
shown that PP1 physically interacts with IRF7. Exogenous expression of PP1 subunits (PP1α, β or 
γ) ablates IKKε-stimulated IRF7 phosphorylation and dramatically attenuates IRF7 
transcriptional activity. Inhibition of PP1 activity significantly increases IRF7 phosphorylation and 
IRF7-mediated IFNα production in response to newcastle disease virus (NDV) infection or Toll-
like receptor 7 (TLR7) challenge, leading to impaired viral replication. In addition, IFN treatment, 
TLR challenges and viral infection induce PP1 expression. Our findings disclose for the first time 
a pivotal role for PP1 in impeding IRF7-mediated IFNα production in host immune responses.
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INTRODUCTION
Interferon (IFN) Regulatory Factor 7 (IRF7) is the “master” regulator of type I IFN (IFN-I) 
in response to pathogenic infections [1, 2], which activate signaling pathways mediated by 
specific pathogen-recognition receptors (PRRs) such as Toll-like receptors (TLRs), RIG-I-
like receptors (RLRs), and the cytosolic receptor cGAMP synthase (cGAS) [2, 3]. 
Phosphorylation of IRF7 is indicative of its activation, and is prerequisite for its function as 
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a transcription factor. Thus, tight regulation of IRF7 phosphorylation and activity is crucial 
for many fundamental processes involving IFN-I, such as antiviral innate immunity, 
autoimmune disorders, and cancers [4–6]. The kinases identified for IRF7 phosphorylation 
include IKKε, TBK1, IRAK1 and IKKα, which phosphorylate IRF7 in a cell type-specific 
manner [1]. Phosphorylation is a dynamic process in the cell that is in general balanced by 
kinases and phosphatases. While IKKε was the first kinase identified for IRF7 
phosphorylation in 2003 [7], the phosphatases that negatively regulate IRF7 phosphorylation 
and activity have not been identified thus far.
PP1 and PP2 together account for more than 90% of the protein phosphatase activity in 
eukaryotes [8, 9]. Recently, the roles of protein phosphatases in antiviral immune response 
have emerged and drew intense attention. PP1 has been shown to dephosphorylate the RNA 
sensors, MDA5 and RIG-I, and promote IFN-I production in response to RNA virus 
infections [10, 11]. Additionally, PP1 interacts with TRAF6, and promotes TRAF6-
dependent innate immune responses [12]. PP1 also dephosphorylates Ebola virus VP30 and 
inhibits its transcription [13]. In contrast, the measles virus V proteins and hepatitis B virus 
(HBV) X protein can antagonize PP1 activity to facilitate their replication [11, 14]. More 
recent reports have shown that PP1 negatively regulates IRF3-mediated IFN-I production by 
inhibiting its phosphorylation at serines 396 and 385 [15], and in conjunction with 
GADD34, regulates TLR-mediated immune response by inhibiting phosphorylation of 
TAK1 and eIF2α [16, 17]. Of special note, PP1 and PP2A are positive regulators of Tat-
dependent HIV1 transcription, and the 35QVCF38 motif of Tat directly interacts with PP1 
[18].
In this study, we show that PP1 interacts with IRF7 and potently inhibits IRF7-mediated 
IFN-I immune responses. We have also shown that TLR challenge or viral infection induces 
PP1 expression.
RESULTS
IRF7 interacts with PP1
No phosphatases have been identified for IRF7 thus far. Recently, the roles of protein 
phosphatases, especially PP1, in antiviral immune response have emerged and drawn intense 
attention [10–17]. To evaluate if PP1 inhibits IRF7 phosphorylation, we first examined the 
possibility that these two proteins can interact. To this end, we analyzed whether IRF7 
protein has potential PP1-binding motifs, the canonical of which has the consensus 
sequence, R/K-X0–1-V/I-X-F/W [9]. The interacting partners identified for PP1, such as 
NIPP1 [19], PNUTS [20, 21], Bcl2 [22], GADD34 [23], Ikaros [24], Inh3 [25], and BRCA1 
[26], all have this binding motif (Fig 1, A). Interestingly, we have identified a conserved 
sequence, RVLF, matching the canonical PP1-binding motif, in both human and mouse IRF7 
proteins. This motif is located at the immediate N-terminus of the DNA-binding domain of 
IRF7 (Fig 1, A). In addition, there is another potential PP1-binding sequence, 408RVFF411, 
located in the very end of C-terminus of human IRF7 protein. However, this sequence is not 
conserved in mouse (Fig 1, A). We then confirmed the protein interaction between IRF7 and 
PP1 by co-immunoprecipitation (Fig 1, B). The interaction between IRF7 and PP1 is 
specific since PP2 did not interact with IRF7 (data not shown). To verify IRF7 and PP1 
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interaction in a biological context, we checked if endogenous IRF7 and PP1 interact in EBV-
transformed cells, in which we have previously shown that IRF7 is expressed at significant 
levels [1]. To this end, IB4, SavIII, and LCL00045, three cell lines transformed with EBV, 
were subjected to co-IP. Results clearly show that PP1 and IRF7 interact endogenously in 
EBV-transformed cells (Fig 1, C). Collectively, these results demonstrate that PP1 and IRF7 
physically interact in vitro and in vivo.
PP1 targets IRF7 key activating phosphorylation sites and dampens IRF7 activity
The key phosphorylation sites of IRF7 responsible for its activation include Ser477, -479, 
-471, and -472 in human IRF7A [27–30]. We show that PP1 targets all the four key 
phosphorylation sites, and remarkably reduces their phosphorylation stimulated by IKKε. 
Moreover, all three isoforms of PP1 have the ability to reduce IRF7 phosphorylation. Flag-
PP1γ seems to have the weakest effect, which is consistent with its expression level that is 
also the weakest (Fig 2, A). Ser471/472 phosphorylation is consistently more sensitive to the 
effect of PP1β, with unknown reason.
We next sought to determine whether PP1 can negatively regulate IRF7 transcriptional 
activity. To this end, Luciferase reporter assays were performed, and results show that all 
three PP1 isoforms strikingly reduce IRF7 activity stimulated by IKKε (Fig 2, B). PP1γ has 
the least effect, in line with its weakest expression level, as shown in Fig 2, A.
To further verify that PP1 targets IRF7 key activating phosphorylation sites, we used the 
IRF7 mutant, Flag-IRF7(S471D/S472D/S477D/S479D) (designated as Flag-IRF7(4D)), a 
phosphomimetic mutant that has constitutive activity since these four key serine sites were 
replaced with aspartic acids [27], for reporter assays. Results show that PP1α dramatically 
reduces TLR7-stimulated WT IRF7 activity, but did not reduce the activity of IRF7(4D), in 
293-TLR7 cells (Fig 2, C).
To assess if PP1 phosphatase activity is required for its inhibition of IRF7, PP1α(T320A) 
that is constitutively active, and PP1α(T320E) that is a phosphatase-dead mutant [31], were 
used for promoter-reporter assays. As shown in Fig 2, D, both WT PP1α and PP1α(T320A), 
but not PP1α(T320E), inhibit IRF7 transactional activity, indicating that the PP1 
phosphatase activity is required for PP1 inhibition of IRF7 phosphorylation.
Further, we assessed the effect of PP1 on IRF7 DNA-binding ability. To this end, 293T cells 
were transfected with indicated plasmids (Fig 2, E). Cells were subjected to ChIP and qPCR 
analyses after 48 h. Results show that PP1 significantly impairs IKKε-stimulated DNA-
binding activity of IRF7, but not of the constitutively active mutantIRF7(4D) (Fig 2, E).
Taken together, these results demonstrated that PP1 targets the key IRF7 phosphorylation 
sites, dampens its phosphorylation and abolishes its transcriptional activity.
Both IRF7 potential PP1-binding sites contribute to its interaction with PP1
To further determine the importance of the potential PP1-binding sites in IRF7 for their 
interactions, we transfected a panel of human 2XMyc-IRF7 point mutants of these two 
potential PP1-binding sites (Fig 3, A), together with Flag-PP1α into 293T cells, and cell 
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lysates were subjected to co-IP. Results show that mutation in either of these sites did not 
disable the interaction between IRF7 and PP1α. When both sites were mutated, however, 
IRF7 lost the ability to interact with PP1 (Fig 3, B), indicating that both sites contribute to 
their interactions. Of note, mutation of either of these two sites abrogates the ability of IRF7 
to transactivate IFNα4 promoter (Fig 3, C), indicating that both of them are essential for 
IRF7 activation. Thus, both motifs contribute to IRF7 binding to PP1 and are required for 
IRF7 activation.
Blockage of PP1 activity potentiates IRF7 phosphorylation and IFNα production in viral 
infection
We further assessed the biological consequences of PP1 blockage of IRF7 activity in viral 
infection. To this end, the human acute myeloid leukemia cell line U937 (monocyte) was 
transfected with plasmids expressing nuclear inhibitor of PP1 (NIPP1), or NIPP1-KTK that 
is defective in its inhibitory activity [32]. Cells were then infected with GFP-NDV 
(Newcastle Disease Virus). NDV is an ssRNA virus that triggers the TLR7 signaling 
pathway (in monocytes and dendritic cells) in addition to RIG-I pathway (in mouse embryo 
fibroblasts), leading to activation of IRF7 for IFN-I production. IRF7 phosphorylation was 
evaluated by flow cytometry after 6 h and IFNα production in medium was measured by 
ELISA after 24 h. As expected, IRF7 phosphorylation is significantly higher in cells 
expressing wild type (WT) NIPP1 (34.0%) compared to that in cells expressing NIPP1-KTK 
(11.8%) (Fig 4, A and B). Correspondingly, IFNα concentration is significantly increased in 
the medium of the cells expressing WT NIPP1 (Fig 4, C). We also assessed the production 
of IL6, which is induced by the TLR7/NFκB signaling axis. Surprisingly, IL6 production is 
significantly decreased in the medium of the cells expressing WT NIPP1 (Fig 4, D), 
suggesting that PP1 is a positive regulator of NFκB activation downstream of TLR7 
signaling in response to virus infection. Consistent with our findings, a recent report show 
that PP1γ interacts with TRAF6, and enhances NFκB-mediated inflammatory responses 
[12]. To ensure the effect on IFNα production is dependent on IRF7, we infected Irf7+/+ and 
Irf7−/− mouse macrophages with NDV, and measured IFNα production. As expected, IFNα 
production is defective in Irf7−/− macrophages (Fig 4, E), indicating that NDV-triggered 
IFNα production depends on IRF7. Collectively, our results show that PP1 is a negative 
regulator of IRF7 phosphorylation and activation, but is likely a positive regulator of TLR7 
activation of NFκB, in innate immune responses.
Blockage of PP1 activity impairs viral replication
Since we show that PP1 inhibits IFNα production, we then evaluated if PP1 can affect GFP-
NDV replication in U937 cells using microscopy (Fig 4, F), and flow cytometry (Fig 4, G). 
Results show that viral replication, represented by GFP expression, is significantly inhibited 
in cells expressing WT NIPP1 than that in cells expressing NIPP1-KTK, indicating that PP1 
promotes viral replication in the cells. We also performed the above experiments in the 
mouse macrophage cell line Raw264.7, and similar results were obtained (data not shown). 
The evaluation of IRF7 phosphorylation, however, was not feasible in Raw264.7 cells due to 
the lack of a commercial antibody against mouse phospho-IRF7.
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In addition, we also used the PP1-specific inhibitor tautomycin (or DMSO control) to treat 
Raw264.7 cells before infection with GFP-NDV (or mock). Tautomycin has been widely 
used for the study of PP1 functions in different contexts [9, 16, 33]. Notably, tautomycin 
treatment results in a remarkable inhibition in viral replication, as shown by GFP-expressing 
cells (Fig 5, A–C), and a remarkable increase in IFNα production (Fig 5, D). The specificity 
of tautomycin on PP1 was verified with the use of the PP1 mutants PP1α(T320A) and 
PP1α(T320E). Results show that the constitutively active mutant PP1α(T320A) (p=0.0029), 
but neither WT (p=0.0870) nor the phosphatase-dead mutant PP1α(T320E) (p=0.4834), 
offsets the effect of tautomycin treatment on IFNα production (Fig 5, E, data for DMSO 
control is not shown), indicating that tautomycin specifically inhibits PP1 activity.
Taken together, these results (Figs 4 and 5) demonstrate that blockage of PP1 activity 
enhances IRF7 transcriptional activity and IFNα production, which impairs viral replication.
PP1 expression is induced during immune responses
To further understand the involvement of PP1 in regulation of IRF7-mediated antiviral 
activity, we examined the possibility that PP1 expression is regulated during antiviral 
responses. U937 cells were treated with IFNα2 or the TLR3 ligand poly(I:C), or infected 
with GFP-NDV. Results show that both treatments (p=0,0266 for IFNα2 and p<0.001 for 
poly(I:C)) and NDV infection (p=0.0015) significantly induce PP1 expression in time-
dependent manners, as evaluated by flow cytometry and immunoblotting (Fig 6). The TLR7 
ligand gardiquimod also consistently induces PP1 expression although its effect is smaller 
(data not shown). Poly(I:C) senses TLR3 signaling, and both TLR3 and TLR7 signaling 
activates IRF7. Thus, we conclude that PP1 is induced during viral infection.
DISCUSSION
Regulation of IRF7 phosphorylation is of paramount importance for controlling antiviral 
immunity in response to viral infection. IRF7 is required not only for IFN priming at early 
stage, but also for IFN amplification at later stages when robust IFN-I production depends 
on a positive regulatory circuit between IRF7 and IFNs [3, 34, 35]. This robust reaction is 
turned off soon after infection under normal physiological conditions, but excessive 
production of IFN-I is fatal to the cell. The underlying mechanism for this shutdown is not 
understood. We show in this study that PP1 targets IRF7 key phosphorylation sites, dampens 
IRF7 phosphorylation and abolishes its activity, and therefore abolishes IFN-I antiviral 
responses.
PP1 exerts its function through interaction with a wide variety of regulatory subunits, which 
function as targeting subunits, substrates and/or inhibitors [8]. These regulatory subunits are 
generally unrelated, but most (about 70%) possess the RVxF motif, a canonical PP1-binding 
sequence, or the motif of FxxR/KxR/K [36]. We have here identified IRF7 as a novel PP1-
interacting factor, and it is targeted by PP1 for dephosphorylation. As the closest family 
member to IRF7, a recent report has shown that IRF3 also interacts with PP1, which 
negatively regulates IRF3 phosphorylation and IRF3-mediated IFN-I production 
downstream of TLR and RLR signaling pathways in macrophages [15]. Interestingly, we 
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have also identified a conserved PP1-binding site, RQVF, in IRF3 protein (spanning aa 213–
216 of human IRF3, data not shown).
The host innate immune system defends against invading pathogens initially by triggering 
signaling pathways mediated by the transmembrane receptors TLRs [37], and cytoplasmic 
receptors that include RLRs [38, 39], NLRs [40], cGAS [41, 42], IFI16 [43], DDX41 [44, 
45], DHX9/36 [46, 47], RNA polymerase III [48], TRIM5α [49], ISG56 [50], LRRFIP1 
[51], MRE11 [52], amongst others. IRF7 is phosphorylated and activated downstream of 
many of these innate immune pathways for induction of IFN-I gene expression (especially 
IFNαs) [1]. Our results are the first to identify PP1 as a phosphatase that targets key 
activating phosphorylation sites of IRF7, attenuating its activity and blocking the IFN-I 
response during viral infection. Thus, our study has addressed an important knowledge gap 
regarding IRF7-mediated IFN-I innate immune response, and has broad significance in 
antiviral innate immunity.
MATERIALS AND METHODS
Constructs, antibodies, and reagents
Flag-PP1 (α, β and γ) expression plasmids cloned in Flag-CMV4 were provided by Dr. 
Sherry Winter [53]. Flag-IRF7 expression plasmids and its mutants were described 
previously [54, 55]. 2XMyc-IRF7 plasmids were generated by subcloning of 2XMyc-IRF7 
fragment (by PCR amplification from pcDNA3-IRF7) into pCMV-Tag3B (Stratagene). 
TLR7 cDNA was cloned from human genome (the human B cell line BJAB) by PCR 
amplification. Deletion and point mutants were generated by site-directed mutation 
(Stratagene), and verified by sequencing. PE-conjugated IRF7(p477/479) antibody (clone 
K47–671) for flow cytometry was purchased from BD Biosciences. The same clone with 
higher concentration but without conjugation was customized for immunoblotting. Mouse 
anti-PP1 (clone E-9), mouse anti-PP1α (clone G-4), goat anti-PP1α (clone C19), mouse 
anti-IRF7 (clone G-8), rabbit anti-IRF7 (clone H-246), goat anti-mouse IgG-HRP, mouse 
anti-rabbit IgG-HRP, and mouse anti-goat IgG-HRP, were purchased from Santa Cruz. Flag 
(clone M2) and Myc (clone 9E10) antibodies were from Sigma and Roche, respectively. 
FITC-, PE-, APC-, and PerCP-eFluor710-conjugated antibodies for flow cytometry were 
purchased from eBioscience. Gardiquimod (designated as “Gardi” in figure legend) and 
HIV-1 ssRNA40 and controls were purchased from Invivogen. IFNα2 was purchased from 
Sigma. Tautomycin was purchased from EMD Millipore.
Cell lines
293 and 293T are human kidney epithelial cell lines, Raw264.7 is mouse macrophage cell 
line, and U937 is a human acute myeloid leukemic cell line. IB4, SavIII, and LCL00045 are 
human B cell lines transformed with EBV. Irf7+/+ and Irf7−/− mouse macrophages were 
gifts from Dr. Kate Fitzgerald. 293-TLR7 stable cell line was generated by transfecting 293 
cells with pcDNA3-TLR7 (human), followed by selection with 0.8 mg/ml G418 for two 
weeks. Epithelial cells and macrophages are cultured with DMEM plus 10% FBS and 
antibiotics. B cells, U937 cells, and mouse macrophages are cultured with RPMI1640 
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medium plus 10% FBS and antibiotics. All cell culture supplies were purchased from Life 
Technologies.
Transfection
293 and 293T cells were transfected with Effectene. U973, Raw264.7, and primary cells 
were transfected with specific Nucleofector kits (Lonza).
Promoter-reporter assays
293 cells were transfected with expression plasmids as indicated together with IFNα4p-Luc 
and Renilla as internal transfection control. Empty vector was used to equalize the total 
amounts of DNA in all transfections. Cells were collected 24 h after transfection. Luciferase 
activity was measured with equal amounts (10% of total for each sample) of protein lysates 
with the use of a Dual Luciferase Assay kit (Promega), on a multimode microplate reader 
(Turner Biosystems). Results are the mean ± standard error (SE) of duplicates for each 
sample. At least three consistent results were obtained from independent experiments and 
representative results are shown. The ability of the empty vector controls to activate 
IFNA4p-Luc was set to 1.
Immunoprecipitation and immunoblotting
293T cells in 60-mm dishes were collected 48 h after transfection. Cells were lysed with 
NP40 lysis buffer, and cell lysates were subjected to immunoprecipitation with 1.5 μg 
indicated antibodies for overnight, and then incubated with 40 μl Protein A/G beads (Santa 
Cruz) for 1 h. After three washes with NP40 lysis buffer, proteins on beads were denatured 
before separated by SDS-PAGE. Immunoblotting was carried out with the indicated 
antibodies and signals were detected with an enhanced chemiluminescence (ECL) kit 
following the manufacturer’s protocol (Amersham Pharmacia Biotech).
Chromosome immunoprecipitation (ChIP)
ChIP was performed with the use of ChIP-IT Express Enzymatic kit (Active Motif). Briefly, 
293T cells were transfected with Flag-IRF7 or its mutants, IKKε, and PP1α expression 
plasmids. Cells were harvested 48 h after transfection, and subjected to crosslinking by 
adding formaldehyde to a final concentration of 1% for 30 min at room temperature with 
slow rotation. Crosslinking was stopped by adding glycine to a final concentration of 125 
mM for 5 min. Shearing and enzymatic digestion of chromatin, IP (with Flag antibody M2, 
Sigma), and DNA recovery were performed following the manufacturers’ instructions. 
qPCR was performed with the human IFNA4 gene promoter primers: F: 5′-
AGCCTTTGAGTGCAGGTG-3′ and R: 5′-TGAACTTCGGCCTCTAGG-3′, and β-actin 
promoter primers (control): 5′-CCAACAAAGCACTGTGG-3′ (forward) and 5′-
GGGCGAAGGCAACGC-3′ (reverse) [56].
Virus infection and TLR7 challenge
GFP-NDV was generously provided by Dr. Christopher Basler with permission from Dr. 
Peter Palese [57]. GFP-NDV (2X104 fluorescent focus forming units (FFU)) was added to 
RAW264.7 and U937 cells and mouse macrophages in serum-free medium, and then 
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incubated at 37ºC for 1.5 h, before complete medium was replaced. For TLR7 challenge, 
cells were incubated with Gardiquimod or HIV1 ssRNA40, with indicated concentrations 
and time-points. Human and mouse IFNα production was measured by ELISA with human 
and mouse VeriKine IFNα ELISA kits (PBL Assay Science), respectively. IL-6 ELISA kits 
were from BioLegend, Inc.
Flow cytometry
Flow cytometry was performed as described previously [58], on an AccuriTM C6 flow 
cytometer (BD) using FlowJo software (Tree Star, Inc). For PP1 expression, cells were fixed 
in fixation buffer (Biolegend) for 20 min, and then washed before incubated with 
permeabilization buffer (eBioscience) for 40 min. Cells were then incubated with PP1 
primary and secondary antibodies and then further incubated anti-CD4 PerCP-Cy5.5 before 
flow cytometry analysis. Live cells from PBMCs were gated for pIRF7 or PP1α expression. 
The gate lines for pIRF7 or PP1α were determined according to corresponding isotope 
controls. All of the isotype controls were negative.
Statistical analysis
The significance of the difference between control and experimental groups was tested using 
Student’s t-test or one-way ANOVA using Graphpad Prism (version 5). p values were 
calculated by unpaired Student’s t-test (between-subjects comparison). p<0.01 (**) and 
P<0.05 (*) were considered significant and p<0.001 (***) was considered very significant. 
For comparisons of multiple groups (more than two), data were analyzed by one-way 
ANOVA and results were adjusted with the Bonferroni’s correction. Data are expressed as 
mean ± standard error (SE) of duplicate samples, and representative results from at least 
three independent experiments are shown.
Acknowledgments
We thank Dr. Christopher Basler and Dr. Peter Palese for generously providing GFP-NDV, Dr. Kate Fitzgerald for 
Irf7+/+ and Irf7−/− mouse macrophages, and Dr. Sherry Winter for PP1 expression constructs. This publication is 
the result of work supported with resources and the use of facilities at the James H. Quillen Veterans Affairs 
Medical Center. The contents in this publication do not represent the views of the Department of Veterans Affairs or 
the United States Government. Grant support: This work was supported by the American Society of Hematology 
Scholar Award to SN, the NIH R01 grants to ZQY/JPM (R01DK093526, R01AI114748), and in part by the NIH 
grant C06RR0306551. The authors declares that they have no competing interests.
Abbreviations
PP1 Protein phosphatase 1
NIPP1 Nuclear inhibitor of PP1
IFN Interferon
IRF7 Interferon regulatory factor 7
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Fig 1. IRF7 interacts with PP1
A. IRF7 protein containsIllustration of IRF7 protein showing the two potential PP1-binding 
sites, which matches PP1-binding consensus sequence R/K-X0–1-V/I-X-F/W. The PP1-
binding core sequences are bold and the contributing amino acids (lysine/arginine proximal 
to, and aspartate/glutamate distal to, the core sequence) are underlined. B. 293T cells were 
transfected with IRF7 and Flag-PP1(α, β, or γ) expression plasmids. Cells were collected 
for immunoprecipitation with mouse anti-IRF7, and immunoblotting was performed with 
Flag antibody or rabbit anti-IRF7. 5% input was probed for PP1 expression with Flag 
antibody. C. Cell lysates prepared from EBV-transformed lymphoblastic cell lines IB4, 
SavIII, and LCL00045 were subjected to IP with mouse anti-PP1 or with mouse IgG control. 
Immunoblotting was performed with rabbit anti-IRF7. Representative results from three 
independent experiments are shown.
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Fig 2. PP1 attenuates IRF7 phosphorylation and transcriptional activity
A. 293T cells were transfected with the plasmids as indicated. Cells were collected and 
subjected to immunoblotting with anti-IRF7 pS477/479 and pS471/472. B. PP1 (α, β, and 
γ) diminishes IKKε-stimulated IRF7 transcriptional activity (*** p<0.0001, one-way 
ANOVA with post hoc Bonferroni t-test). 293 cells were transfected with IRF7 and Flag-PP1 
(α, β, or γ), and IKKε expression plasmids, pGL3/ISRE-Luc, and Renilla. Dual luciferase 
assays were performed 24 h after transfection. The ability of the vector control to activate 
the promoter construct was set to 1. C. Cells were treated with the TLR7 ligand gardiquimod 
before subjected to dual luciferase assays (*** p<0.0001, unpaired t test). D. 293 cells were 
transfected with IRF7, IKKε, and WT PP1α (or its mutants) expression plasmids, pGL3/
ISRE-Luc, and Renilla. Dual luciferase assays were performed 24 h after transfection. WT 
PP1α, constitutively active mutant PP1α(T320A), phosphatase-dead mutant PP1α(T320E). 
One-way ANOVA with post hoc Bonferroni t-test was performed. ***p=0.0010, 
**p=0.0017, n.s.: non-specific. E. 293T cells were transfected with IRF7 or IRF7(4D), 
IKKε and PP1. Cells were subjected to ChIP after 48 h. DNA pellets were used for qPCR 
using the IFNA4 promoter primers. (***p=0.0005, unpaired t test). Representative results 
from at least three independent experiments are shown.
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Fig 3. Both PP1-binding motifs on IRF7 are required for its interaction with PP1 and for its 
activation
A. A diagram showing the potential PP1-binding sites on IRF7 and point mutation. B. 293T 
cells were transfected with Flag-PP1α, 2XMyc-IRF7 or its mutants. Cells were collected for 
IP with Myc antibody. Immunoblotting was performed with Flag or Myc antibody. C. 293 
cells were transfected with 2XMyc-IRF7 or its mutants, IKKε, Flag-PP1α, pGL3/ISRE-Luc, 
and Renilla. Cells were collected 24 h later for dual luciferase assays. Representative results 
from three independent transfection experiments are shown.
Wang et al. Page 15
Eur J Immunol. Author manuscript; available in PMC 2017 October 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
Fig 4. Inhibition of PP1 activity enhances IRF7 phosphorylation and IFNα production, and 
impairs viral replication in U937 cells
A–D and F–G. U937 cells were transfected with Flag-tagged WT-NIPP1 or its mutant 
NIPP1-KTK. Cells were then infected with GFP-NDV and analysed by flow cytometry for 
IRF7 phosphorylation (A–B). Cell culture medium was tested for (C) IFNα and (D) IL6 
production by ELISA. E. Irf7+/+ and Irf7−/− mouse macrophages were infected with GFP-
NDV. IFNα production was measured by ELISA F and G. GFP expression in U937 cells 
was analysed by fluorescence microscopy (F), or flow cytometry (G), Scale bar=10 μm. 
***p<0.0001, unpaired t test. Results are from a single experiment representative of three 
independent transfection experiments.
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Fig 5. Inhibition of PP1 activity potentiates IFNα production and impairs viral replication in 
Raw264.7 cells
A–D. Raw264.7 cells were treated with tautomycin (or DMSO control) and then infected 
with GFP-NDV. GFP expression was evaluated by (A) fluorescence microscopy or (B–C) 
flow cytometry. Scale bar=10 μm. D. IFNα and IL6 production in the medium of Raw264.7 
cells was measured by ELISA and normalized by GFP-expressing cell numbers. 
***p<0.0001, unpaired t test. E. Raw264.7 cells were transfected with empty vector, WT 
PP1α or its mutants. Subsequently, cells were treated with tautomycin (or DMSO control) 
and infected with GFP-NDV as in A. One-way ANOVA with post hoc Bonferroni t-test was 
performed. *p=0.0029. Results are from a single experiment representative of three 
independent experiments.
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Fig 6. PP1 is induced during antiviral immune responses
U937 cells were treated with IFNα2 (A and B), or Poly(I:C) (C), or GFP-NDV (D) at 
indicated time points. Cells were then fixed and permeabilized before incubation with the 
mouse anti-PP1α (nd then with the F(ab’)2 anti-mouse IgG and analysed by flow cytometry 
(A, C and D), or subjected to immunoblotting (B), for PP1 expression. Linear regression 
analysis was performed. *p<0.05 (A), ***p<0.001 (C), **p<0.01 (D). Results are from a 
single experiment representative of three independent experiments.
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